ERSPC published findings

Schröder FH, Hugosson J. Roobol MJ et al. Prostate-Cancer Mortality at 11 Years of Follow-up. New Engl J Med 2012;366;11.

Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. New Engl J Med 2009; 360:1320-1328.

Roobol MJ, et al. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56, Issue 4 584-591.

Prostate cancer risk calculator, further reading

Roobol MJ, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012; 61: 577-583.

Bul M, Delongchamps NB, Steyerbergt EW. et al. Updating the prostate cancer risk indicator for contempotary biopsy schemes. The Canadian Journal of Urology April 2011; (18(2).

Trottier G, Roobol MJ et al. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJUI 2011

Roobol MJ, Kranse R, Maattanen L, Schröder FH. External validation of the Risk indicator®. ERSPC Rotterdam,Helsinki and Tampere. Eur Urol Suppl 2009.

Kranse R, Roobol MJ, Schröder FH. A graphical device to represent the outcomes of a logistic regression analysis, an illustration of its possible use in prostate cancer screening and prostate cancer treatment counseling. Prostate 2008; 68:1674 ^1680 .

Contact Information

Monique Roobol
Risk Calculator Administrator

Your Feedback

Tell us what you think about the risk calculators and what your experience has been.

We would welcome your feedback.